Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-ENPP3/anti-CD3 bispecific antibody JNJ-87890387

A human bispecific antibody directed against both ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3; NPP3; B10; PDNP3; CD203c; PD-IBETA) and the T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-ENPP3/anti-CD3 bispecific antibody JNJ-87890387 targets and binds to ENPP3 expressed on tumor cells and CD3 expressed on T cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against ENPP3-expressing tumor cells. While normally expressed at low levels on tubules of the kidney cortex and by some cells in gastrointestinal, adrenal, and endometrial tissues, the type II transmembrane glycoprotein ENPP3 is overexpressed in various cancers including most renal neoplasms and some liver cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-ENPP3/anti-CD3 bispecific ENPP3 T-cell redirector JNJ-87890387
anti-ENPP3/anti-CD3 T-cell redirector JNJ-87890387
anti-ENPP3/CD3 bispecific antibody JNJ-87890387
anti-ENPP3/CD3 bispecific ENPP3 T-cell redirector JNJ-87890387
ENPP3 x CD3 bispecific antibody JNJ-87890387
T-cell engager JNJ-87890387
TCE JNJ-87890387
Code name:JNJ 87890387
JNJ-87890387
JNJ87890387
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search